Evaluation of cytochrome P450 (CYP) induction using RT-qPCR in exosomes isolated from plasma samples: Method development and qualification

Plasma exosome isolation, CYP mRNA quantification (CYP1A2, CYP2B6, CYP3A4) by RT-qPCR, validation as enzymatic induction biomarker for DDI assessment in preclinical and clinical settings

This work develops and qualifies a method for plasma exosome isolation and CYP enzyme mRNA quantification (CYP1A2, CYP2B6, CYP3A4) by RT-qPCR, for use as a non-invasive biomarker of enzymatic induction. The method is validated in human and murine samples with reproducible analytical performance. It represents a non-invasive alternative to liver biopsies and cell models for drug-drug interaction assessment via induction, particularly to detect phenoconversion induced by CYP-inducing drugs.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Drug-induced enzymatic phenoconversion is an underrecognized mechanism of therapeutic failure or toxicity. This exosomal biomarker could enable non-invasive in vivo enzymatic induction monitoring to guide dose adjustments during treatment, with applications in oncology (combined treatments), transplantation, and psychiatry.

Analysis by Dr Thibaut Benquey